Novartis Cosentyx® receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis

/PRNewswire/ -- Novartis, a leader in rheumatology and immuno-dermatology, today announced the US Food and Drug Administration (FDA) has approved Cosentyx®...

Related Keywords

United States ,Cincinnati ,Ohio ,American ,Hermine Brunner ,Pabout Cosentyx ,Dermatol Venereol ,Victor Bulto ,Prnewswire Novartis ,Twitter ,Rheumatology Research Alliance Registry ,Ministry Of Health ,Drug Administration ,American College Of Rheumatology ,Us Pharmaceuticals ,Novartis ,Exchange Commission ,International League ,Novartis Europharm ,American Academy Of Dermatology ,Nj Novartis Pharmaceuticals Corporation ,Novartis Pharmaceuticals Corporation ,Novartis Pharmaceuticals Corp ,Cincinnati Children ,Novartis Pharmaceuticals ,Medication Guide ,Prescribing Information ,East Hanover ,Pharmaceuticals Corporation ,Enthesitis Related Arthritis ,Juvenile Psoriatic Arthritis ,Primary Results ,Treatment Withdrawal ,American College ,Childhood Arthritis ,Rheumatology Research Alliance ,Treatment In Children And Adolescents ,Efficacy And Safety Results From ,American Academy ,Virtual Meeting Experience ,Analysis Report ,Pharmaceuticals Corp ,Pooled Safety ,